Please ensure Javascript is enabled for purposes of website accessibility

iNexin Ophthalmic Solution


Phase 1

Phase 2

Phase 3





iNexin eye drops pipeline

iNexin Ophthalmic Solution

Investigating indications with significant unmet medical needs

Corneal Injury

The bulk of eye trauma related emergency visits are due to corneal injury. These can be trauma or exposure induced, and the resulting injuries span from discomfort to vision-threatening.

Retinal Diseases

Retinal Diseases impact the back of the eye, and often result in visual symptoms. While some causes do have treatments, many do not, and there is a lot of room to improve patient outcomes.

iNexin Ophthalmic Solution for the treatment of corneal injury has the potential to improve patient outcomes by regulating inflammatory response to promote improved ocular healing.

In initial studies, iNexin demonstrated:

Acceleration of corneal re-epithelialization

Reduction of corneal edema and inflammation

Restoration of the ocular surface

Safe and tolerable delivery

Revolutionizing the Way the Body Responds to Injury

Xequel’s aCT1 technology platform is designed to stimulate healing by creating an improved injury response. Our proprietary aCT1 technology restores the gap junctions to normalize cell-to-cell signaling and facilitate proper healing.